Type 1 diabetes (T1D) results from the autoimmune destruction of β cells. Cure of established T1D requires both reversal of autoimmunity and regeneration of β cells. Autoimmune NOD mice closely resemble human T1D. We have reported that administration of gastrin and epidermal growth factor (GE) allows β cell regeneration and cure of late-stage T1D in NOD mice after reversal of autoimmunity by induction of MHC-mismatched mixed chimerism. β cell regeneration in non-autoimmune diabetic mice can come from differentiation of Sox9+ pancreatic ductal progenitors, parenchymal progenitors, and transdifferentiation of α cells. However, the source of β cell regeneration in autoimmune NOD mice remains unclear.

Using NOD mice with inducible Sox9-EGFP, we found that Sox9+ pancreatic ductal progenitors only accounted for a small fraction of total β cell regeneration. Using Nestin-EGFP mice, we did not see any β cells originating from Nestin+ parenchymal progenitor cells.

Using NOD mice with inducible glucagon-RFP, we found that ∼50% of regenerated β cells were from α cell transdifferentiation in mice after induction of mixed chimerism and GE, although mixed chimerism alone induced few α to β cell transdifferentiation in mice. In addition, using NOD mice with inducible insulin-EGFP, we found that the majority of residual β cells in late-stage diabetic NOD mice were insulinlo, and they became insulinhi after induction of mixed chimerism and GE treatment.

Taken together, transdifferentiation of α to β cells and re-differentiation of insulinlo cells are the major sources of β cell regeneration in late-stage diabetic NOD mice after induction of mixed chimerism and administration of GE. How hyperglycemia and GE differentially regulate α cell transdifferentiation and β cell re-differentiation is under investigation. This work is supported by the Wanek Family fund.

Disclosure

S. Tang: None. M. Zhang: None. P. Santamaria: Board Member; Self; Parvus Therapeutics. A.D. Riggs: None. L. Jin: None. D. Zeng: None.

Funding

Todd and Karen Wanek Family Foundation Ltd.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.